Reviews
CAR-T Cell Therapy in Pediatric B-ALL: Overcoming Resistance and Trial Bottlenecks
Xu et alFrontiers in immunology

In relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL), chimeric antigen receptor (CAR)-T cell therapy achieves remission rates exceeding 80%, yet a therapeutic ceiling persists as 40% to 50% of patients eventually relapse within the first year.
According to the authors, this barrier results from the convergence of at least four interrelated biological layers: loss of CAR-T cell persistence, antigen escape driven by CD19 splicing variants and lineage switch, CAR-T cell-intrinsic exhaustion induced by chronic tonic signaling, and an immunosuppressive bone marrow microenvironment that actively extinguishes effector function.
Beyond molecular resistance mechanisms, substantial translational bottlenecks persist within the clinical pipeline. A systematic analysis of 226 pediatric-eligible CAR-T clinical trials showed that 95.6% are Phase I–II studies, only 3.5% (8 of 226) are registered as Phase III/IV, and 56.9% (58 of 102) of completed trials had no outcome recorded in the source database.
The authors evaluate emerging engineering strategies—spanning dual-targeting and armored CAR architectures to CRISPR-edited allogeneic products and in vivo mRNA delivery—and argue that therapeutic progress depends on both smarter receptor design and structural reforms in trial design, outcome transparency, and global collaboration.
Key Takeaways
- Although CAR-T cell therapy achieves remission rates exceeding 80% in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia, 40% to 50% of patients relapse within the first year.
- A systematic analysis of 226 pediatric-eligible CAR-T clinical trials found that 95.6% are Phase I–II, 3.5% (8/226) are Phase III/IV, and 56.9% (58/102) of completed trials had no outcome recorded in the source database.
Read the original sourceFrontiers in immunology
